Tianjin Medical University Cancer Institute and Hospital: all 490 studies

Page 3 of 5. Open to participants first (289), then studies with results posted, then the rest; newest registration first within each.

• Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II StudyRecruitingNCT06404840Phase 2
• Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06395870Phase 1
• Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsRecruitingNCT06383559Phase 2
• A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCCNot yet recruitingNCT06375642Phase 2
• Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.RecruitingNCT06375486Phase 2
• Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) PatientsRecruitingNCT06370065Phase 2
• Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II TrialRecruitingNCT06363734Phase 2
• To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung CancerRecruitingNCT06352008Phase 2
• Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRCNot yet recruitingNCT06322563Phase 2
• Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invasion.RecruitingNCT06317324
• Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety StudyRecruitingNCT06301399Phase 2
• A Single-Arm Clinical Trial of Percutaneous Splenic Ablation Combined With Splenic Artery Occlusion for Secondary Hypersplenism.RecruitingNCT06292715Not applicable
• Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract CancerRecruitingNCT06282120
• Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic CancerNot yet recruitingNCT06259058Phase 1/2
• Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)RecruitingNCT06221670Phase 2
• A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With ChemotherapyRecruitingNCT06208826Phase 2
• The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic CancerRecruitingNCT06208436
• A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk FactorsNot yet recruitingNCT06143735Phase 2
• Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung CancerRecruitingNCT06141226Phase 2
• Fruquintinib Combined With TAS102 for Advanced Gastric CancerRecruitingNCT06102785
• Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric CancerRecruitingNCT06102772
• Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody FailedRecruitingNCT06102759
• Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine CarcinomaRecruitingNCT06102746
• Induction Toripalimab and Chemotherapy in Locally Advanced Cervical CancerRecruitingNCT06093438Phase 1/2
• Tislelizumab Plus Concurrent Chemoradiation in Older With ESCCRecruitingNCT06061146Phase 2
• The Possible Range of No.12a Lymph Node Dissection of Locally Advanced Gastric CancerRecruitingNCT06033482
• A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal AdenocarcinomaRecruitingNCT05997147
• Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung CancerRecruitingNCT05975944Phase 1/2
• Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric CancerNot yet recruitingNCT05974059Phase 2
• Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC PatientsEnrolling by invitationNCT05947825Phase 2
• A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line ChemotherapyRecruitingNCT05890287Not applicable
• Pre-pectoral Breast Reconstruction With or Without MeshRecruitingNCT05888571Not applicable
• Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI ResearchRecruitingNCT05885776Phase 2
• A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete RemissionNot yet recruitingNCT05874778Phase 2
• H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein ThrombosisNot yet recruitingNCT05872841Phase 2
• HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular CarcinomaRecruitingNCT05864755Phase 2
• Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyRecruitingNCT05856864Phase 1
• Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ CancerRecruitingNCT05853172Phase 2
• Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)Not yet recruitingNCT05842018Phase 2
• A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/RadiotherapyNot yet recruitingNCT05828875
• HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular CarcinomaNot yet recruitingNCT05821361Phase 2
• Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract CancerRecruitingNCT05820906Phase 2
• Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI TherapyNot yet recruitingNCT05806671Phase 2
• Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-MutationNot yet recruitingNCT05778149Phase 2
• Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)RecruitingNCT05686434Phase 2
• Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's LymphomaEnrolling by invitationNCT05683704Phase 2
• Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic CancerRecruitingNCT05679050Phase 2
• AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFHEnrolling by invitationNCT05678933Phase 3
• Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence RiskRecruitingNCT05672537Phase 2
• Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 AlterationsRecruitingNCT05651672Phase 2
• A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic TumoursRecruitingNCT05644392Phase 1
• Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract CancerRecruitingNCT05640791Phase 2
• Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell CarcinomaRecruitingNCT05637268Phase 2
• Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT05616390Phase 2
• Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck CancerRecruitingNCT05595590Phase 2
• Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular CarcinomaNot yet recruitingNCT05582109Phase 2
• A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR AlterationsRecruitingNCT05560334Phase 2
• Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI TherapyNot yet recruitingNCT05560308Not applicable
• Second Line Therapy for Advanced Intrahepatic CholangiocarcinomaNot yet recruitingNCT05535647Phase 2
• Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaRecruitingNCT05519410Phase 2
• A Phase II Study of CRT Combined With QL1706 in ESCC PatientsRecruitingNCT05490719Phase 2
• CMOEP in the Treatment of Untreated Peripheral T-cell LymphomaNot yet recruitingNCT05458180Phase 1
• Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT05449483Phase 2
• PD1 and PARP for Maintenance Therapy in NSLLCRecruitingNCT05392686Phase 2
• An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder CancerNot yet recruitingNCT05356351Phase 2
• GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced CholangiocarcinomaRecruitingNCT05215665Not applicable
• Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical CancerRecruitingNCT05084677Phase 2
• Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRCRecruitingNCT05077839Phase 2
• Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic CancerRecruitingNCT05035147Phase 4
• A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast CancerRecruitingNCT04970264
• Breast Mesh Used in Two-staged Breast ReconstructionRecruitingNCT04967976Not applicable
• Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)Not yet recruitingNCT04965831Phase 2
• Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT04908566Phase 2
• Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT04907344Phase 2/3
• Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast CancerNot yet recruitingNCT04900311Phase 2
• Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)Not yet recruitingNCT04846634Phase 2
• A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric CancerRecruitingNCT04843215Not applicable
• Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)RecruitingNCT04807673Phase 3
• Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal CarcinomaRecruitingNCT04782765Phase 2
• Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLCRecruitingNCT04631770Not applicable
• Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLCRecruitingNCT04530227Phase 2
• A Trial of Total Versus Partial Omentectomy for Advanced Gastric Cancer in GastrectomyRecruitingNCT04108494Not applicable
• Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.RecruitingNCT03992885Phase 3
• Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal CancerRecruitingNCT03950154Phase 3
• Outcome of Resection for Colorectal CancerEnrolling by invitationNCT03837782Not applicable
• Neck Dissection vs Radiotherapy for Cervical Metastases in Advanced Hypopharyngeal CancerNot yet recruitingNCT03367884Not applicable
• Radiotherapy vs Neck Dissection for Clinical T1/2N0 Supraglottic CancerNot yet recruitingNCT03358602Not applicable
• XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring CarcinomaNot yet recruitingNCT03355612Phase 3
• Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast CancerRecruitingNCT02506361
• Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVIActive, not recruitingNCT07658105Phase 2
• Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.Active, not recruitingNCT07654530Phase 2
• Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic CholangiocarcinomaActive, not recruitingNCT07646717Phase 2
• A Pan-Cancer Retrospective Study on the Relationship Between Tumor Microenvironment Composition and Efficacy of Antibody-Based Antitumor TherapyActive, not recruitingNCT07584044
• Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II StudyActive, not recruitingNCT07491159Phase 1/2
• Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced DiarrheaCompletedNCT07460596Phase 2
• A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid TumorsWithdrawnNCT07449481Phase 2
• A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid TumorsActive, not recruitingNCT07407985Phase 1
• Prognostic Model of Elderly Hodgkin Lymphoma in ChinaActive, not recruitingNCT07374068
• Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver CancerActive, not recruitingNCT07298538
• An Exploratory Study on Microbial Biomarkers Associated With the Efficacy of Neoadjuvant TherapyCompletedNCT07263620

← Tianjin Medical University Cancer Institute and Hospital overview and focus areas